Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars

Executive Summary

Mylan's Kokino spoke with Scrip about what he called the successful launch of the company's first biosimilar in the US, a version of Amgen's Neulasta, the state of the US biosimilar market and resetting expectations.

Advertisement

Related Content

Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?
From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive
Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value
Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown
Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky
Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel